TREM1 and Sepsis: Given the absence of FDA-approved TREM-1 inhibitors, recent research has focused on identifying small molecules capable of modulating TREM-1 expression and activity, offering potential breakthroughs in the treatment of sepsis, inflammatory diseases, and immune disorders.